Connect Biopharma is trading 6.4% up at $2.34, with no clear catalyst identified.
- No new company-specific announcement was identified for September 1, 2026; the latest material update remains the August 12 quarterly report.
- The report confirmed completed enrollment in both Phase 2 Seabreeze STAT studies and anticipated September topline results.
- Recent Buy and Outperform analyst coverage may support sentiment, while weak biotechnology sentiment and lower major U.S. indices leave the gain’s precise catalyst unclear.